DXd Monoclonal Antibody

Cat.#: 176730

Size:

Special Price 322.6 USD

Availability: In Stock
- +

Add to cart to get an online quotation

Product Information

  • Product Name
    DXd Monoclonal Antibody
  • Documents
  • Description
    Product has been tested in direct ELISA.
  • Tested applications
    ELISA
  • Species reactivity
    Chemical
  • Isotype
    Mouse IgG1, κ
  • Preparation
    DXd conjugated with BSA. Protein G affinity purified
  • Clonality
    Monoclonal
  • Formulation
    PBS(pH7.4), lyophilized. Reconstitution: Adding sterile water, prepare a stock solution of 2.0 mg/ml.
  • Storage instructions
    Store at -20℃. Avoid freeze / thaw cycles.
  • Applications
    ELISA: 1:5,000-1:20,000
  • Validations

    ELISA Binding Assay of Anti-Dxd Antibody to different proteins.

    ELISA Binding Assay of Anti-Dxd Antibody to different proteins.

    ELISA analysis of Anti-Dxd Monoclonal Antibody with Dxd-BSA, BSA and Dxd ADC. Anti-Dxd Monoclonal Antibody can bind to Dxd-BSA or Dxd ADC but not carrier protein.

    ELISA Binding Assay of Anti-Dxd Antibody

    ELISA Binding Assay of Anti-Dxd Antibody

    Immobilized Dxd ADC at 2μg/mL (100μL/well) can bind anti-Dxd mouse monoclonal antibody.

  • Background
    DXd is a derivative of Exatecan (DX-8951). Dxd (Deruxtecan) is a potent DNA topoisomerase I inhibitor with an IC50 of 0.31 µM, of 10-fold potency compared to the active metabolite of irinotecan (SN-38) in vitro. Dxd has been used as the conjugated payload of the HER2-targeting ADC (DS-8201a) and some other ADCs.
  • References
    • Ogitani Y, Aida T, Hagihara K, et al. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1Preclinical Efficacy of DS-8201a, a Novel HER2-Targeting ADC[J]. Clinical Cancer Research, 2016, 22(20): 5097-5108.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"